IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 77.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 374 shares of the medical research company’s stock after selling 1,314 shares during the period. Raleigh Capital Management Inc.’s holdings in IQVIA were worth $73,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Mutual Advisors LLC boosted its stake in shares of IQVIA by 14.8% in the fourth quarter. Mutual Advisors LLC now owns 1,689 shares of the medical research company’s stock valued at $334,000 after buying an additional 218 shares in the last quarter. Janney Montgomery Scott LLC lifted its holdings in IQVIA by 3.3% in the fourth quarter. Janney Montgomery Scott LLC now owns 36,512 shares of the medical research company’s stock valued at $7,175,000 after acquiring an additional 1,172 shares during the period. Advisory Alpha LLC boosted its position in shares of IQVIA by 18.2% during the 4th quarter. Advisory Alpha LLC now owns 3,189 shares of the medical research company’s stock worth $627,000 after purchasing an additional 492 shares in the last quarter. Howard Capital Management Group LLC grew its stake in shares of IQVIA by 1.5% during the 4th quarter. Howard Capital Management Group LLC now owns 121,894 shares of the medical research company’s stock worth $23,953,000 after purchasing an additional 1,860 shares during the period. Finally, Clear Harbor Asset Management LLC increased its holdings in shares of IQVIA by 57.8% in the 4th quarter. Clear Harbor Asset Management LLC now owns 6,262 shares of the medical research company’s stock valued at $1,231,000 after purchasing an additional 2,293 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of research analyst reports. Stephens initiated coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective on the stock. Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday. Redburn Atlantic started coverage on IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. TD Cowen decreased their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. dropped their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Stock Up 0.3 %

IQV stock opened at $206.06 on Friday. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The stock has a market capitalization of $37.40 billion, a P/E ratio of 27.04, a PEG ratio of 2.14 and a beta of 1.48. The company has a 50 day moving average price of $199.41 and a two-hundred day moving average price of $221.19. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.